9:01AM Seattle Genetics and Millennium expand antibody-drug conjugate collaboration (SGEN) 14.60 : Co announces that Millennium, a wholly owned subsidiary of Takeda Pharmaceutical has paid an undisclosed fee to exercise an option to designate a second antigen target under the parties' existing antibody-drug conjugate collaboration. Millennium is responsible for research, product development, manufacturing and commercialization of any ADC products resulting from the collaboration. Co is entitled to receive progress-dependent milestone payments and mid-single digit royalties from Millennium on worldwide net sales of any resulting ADC products.
Market Data 
Markets 
AI
